drugset
drugset / Trial / NCT05476107

SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects

NCT05476107 ↗

Phase 1 Completed 50 enrolled Applied Molecular Transport
RandomizedSequentialTriple-blindTreatment

Summary

Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of AMT-126 and Optional Pharmacoscintigraphic Assessment of Oral AMT-126

Timeline

Start
2021-02-26
Primary completion
2022-03-26
Completion
2022-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-126 Unknown — Oral

Indications

No indication recorded.